It has been shown using immunohistochemical staining and Kaplan–Meier survival analysis that high eIF3d expression is tightly associated with worse prognoses in patients with gastric, gallbladder, lung, and liver cancers (21, 57, 60, 79), whereas eIF3d expression in prostate cancer associates with better prognosis (70). The gene discussed is EIF3D; the disease is prostate cancer.